vistide
gilead sciences international limited - cidófóvír - cytomegalovirus retinitis - veirueyðandi lyf til almennrar notkunar - vistide er ætlað til meðferðar við cýtómegalóveiru retinitis hjá sjúklingum með fengið ónæmisbrestsheilkenni (aids) og án skerta nýrnastarfsemi. vistide ætti aðeins að nota þegar aðrir lyf eru talin óviðeigandi.
drovelis
gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - hormón kynlíf og stillum kynfæri - oral contraceptive.
lydisilka
estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - hormón kynlíf og stillum kynfæri - getnaðarvörn til inntöku. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.
voraxaze
serb sas - glucarpidase - metabolic side effects of drugs and substances - Öll önnur lækningavörur - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.
asubtela (ethinylestradiol/drospirenon 0,03 mg/3 mg focus) filmuhúðuð tafla 3 mg/ 0,03 mg
exeltis healthcare s.l. - drospirenonum inn; ethinylestradiolum inn - filmuhúðuð tafla - 3 mg/ 0,03 mg
harmonet tafla 75 míkróg+ 20 míkróg
pfizer aps (p) - gestodenum inn; ethinylestradiolum inn - tafla - 75 míkróg+ 20 míkróg
cleodette filmuhúðuð tafla 3 mg/0,02 mg
teva b.v.* - drospirenonum inn; ethinylestradiolum inn - filmuhúðuð tafla - 3 mg/0,02 mg
mercilon tafla 150 míkróg/20 míkróg
n.v. organon* - desogestrelum inn; ethinylestradiolum inn - tafla - 150 míkróg/20 míkróg
nuvaring leggangainnlegg 0,120 mg/0,015 mg/24 klst.
n.v. organon* - etonogestrelum inn; ethinylestradiolum inn - leggangainnlegg - 0,120 mg/0,015 mg/24 klst.
ornibel leggangainnlegg 0,120mg / 0,015 mg/24 klst.
exeltis healthcare s.l. - etonogestrelum inn; ethinylestradiolum inn - leggangainnlegg - 0,120mg / 0,015 mg/24 klst.